AriBioLab Co.,Ltd. (KOSDAQ:261780)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,380.00
-140.00 (-5.56%)
At close: Jul 20, 2026
Market Cap63.51B -25.4%
Revenue (ttm)331.78M -57.2%
Net Income-15.54B
EPS-578.52
Shares Out 26.91M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume215,001
Open2,520.00
Previous Close2,520.00
Day's Range2,365.00 - 2,570.00
52-Week Range2,240.00 - 6,720.00
Beta0.10
Analystsn/a
Price Targetn/a
Earnings Daten/a

About AriBioLab

AriBioLab Co.,Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes a 3rd generation prophylactic HBV vaccine in Phase IIb planning for hepatitis B prevention, and an adjuvanted HBV therapeutic vaccine in Phase I/IIa for chronic hepatitis B treatment. It also features a VZV (Shingles) vaccine currently in Phase I for the prevention of Herpes Zoster. Additionally, an influenza vaccine for seasonal flu, recombinant MBL for infectious ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 261780
Full Company Profile

Financial Performance

In 2025, AriBioLab's revenue was 158.62 million, a decrease of -57.21% compared to the previous year's 370.66 million. Losses were -16.04 billion, 58.3% more than in 2024.

Financial Statements